Pulse.

a daily field guide to health research that matters

◆ Console

‹ Tue · 27 Oct 2026
Standard addition

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

An antibody-drug conjugate significantly extends survival for endometrial cancer patients who've already exhausted chemotherapy and immunotherapy.

This study aimed to compare sac-TMT with the treatment of physician's choice (TPC) in patients with endometrial cancer who had been previously treated with platinum-based chemotherapy and immunotherapy. Sac-TMT significantly improved progression-free survival and overall survival versus TPC in patients with advanced or recurrent endometrial cancer previously treated with platinum-based chemotherapy and immunotherapy.

What the study was

Study design
Randomized controlled trial
Sample size
390
Category
Treatment Innovation
Maturity
Potentially Practice-Changing
Journal
Lancet

Why it surfaced

Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 8/10.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.